Ultragenyx Pharmaceutical RARE Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets?
- Ultragenyx Pharmaceutical (RARE) reported deferred tax assets and other non-current assets of $61M in Q1 2026.
- How has Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets changed year-over-year?
- Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets decreased by 2.2% year-over-year, from $62.37M to $61M.
- What is the long-term trend for Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's deferred tax assets and other non-current assets has grown at a 46.8% compound annual growth rate (CAGR), from $8.81M to $60M.